HRP20110129T1 - Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol - Google Patents
Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol Download PDFInfo
- Publication number
- HRP20110129T1 HRP20110129T1 HR20110129T HRP20110129T HRP20110129T1 HR P20110129 T1 HRP20110129 T1 HR P20110129T1 HR 20110129 T HR20110129 T HR 20110129T HR P20110129 T HRP20110129 T HR P20110129T HR P20110129 T1 HRP20110129 T1 HR P20110129T1
- Authority
- HR
- Croatia
- Prior art keywords
- trans
- tetrahydrocannabinol
- composition
- crystalline
- dosage form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 58
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 18
- 239000003937 drug carrier Substances 0.000 claims abstract 13
- 239000003814 drug Substances 0.000 claims abstract 10
- 239000002552 dosage form Substances 0.000 claims 35
- 239000012071 phase Substances 0.000 claims 21
- 229930003827 cannabinoid Natural products 0.000 claims 18
- 239000003557 cannabinoid Substances 0.000 claims 18
- 239000012074 organic phase Substances 0.000 claims 18
- 239000003518 caustics Substances 0.000 claims 15
- 239000003495 polar organic solvent Substances 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 10
- 238000013270 controlled release Methods 0.000 claims 10
- 230000002051 biphasic effect Effects 0.000 claims 9
- 239000000843 powder Substances 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 229940065144 cannabinoids Drugs 0.000 claims 7
- 238000002425 crystallisation Methods 0.000 claims 6
- 230000008025 crystallization Effects 0.000 claims 6
- 238000002156 mixing Methods 0.000 claims 6
- 238000000926 separation method Methods 0.000 claims 6
- 230000001476 alcoholic effect Effects 0.000 claims 5
- 239000011159 matrix material Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 208000016261 weight loss Diseases 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 229920001800 Shellac Polymers 0.000 claims 2
- 230000004596 appetite loss Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims 2
- 208000019017 loss of appetite Diseases 0.000 claims 2
- 235000021266 loss of appetite Nutrition 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- -1 multiparticles Substances 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 235000013874 shellac Nutrition 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000001993 wax Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 229920001971 elastomer Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 239000005060 rubber Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01B—CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES
- H01B3/00—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties
- H01B3/02—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of inorganic substances
- H01B3/10—Insulators or insulating bodies characterised by the insulating materials; Selection of materials for their insulating or dielectric properties mainly consisting of inorganic substances metallic oxides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69136105P | 2005-06-16 | 2005-06-16 | |
| US72650905P | 2005-10-12 | 2005-10-12 | |
| PCT/EP2006/005761 WO2006133941A2 (fr) | 2005-06-16 | 2006-06-14 | Ingredient pharmaceutique actif a base de cannabinoides pour formes posologiques ameliorees |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110129T1 true HRP20110129T1 (hr) | 2011-03-31 |
Family
ID=36922253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110129T HRP20110129T1 (hr) | 2005-06-16 | 2011-02-23 | Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20070072939A1 (fr) |
| EP (3) | EP1901734B1 (fr) |
| JP (2) | JP2008543800A (fr) |
| KR (3) | KR20100102237A (fr) |
| AP (1) | AP2405A (fr) |
| AR (1) | AR054064A1 (fr) |
| AT (1) | ATE489085T1 (fr) |
| AU (1) | AU2006257059C1 (fr) |
| BR (1) | BRPI0612922A2 (fr) |
| CA (1) | CA2612061A1 (fr) |
| CR (2) | CR9662A (fr) |
| CY (1) | CY1111446T1 (fr) |
| DE (1) | DE602006018466D1 (fr) |
| DK (1) | DK1901734T3 (fr) |
| EA (1) | EA016813B1 (fr) |
| EC (1) | ECSP078023A (fr) |
| HK (1) | HK1118447A1 (fr) |
| HR (1) | HRP20110129T1 (fr) |
| IL (1) | IL188150A0 (fr) |
| MA (1) | MA29630B1 (fr) |
| MX (1) | MX2007016051A (fr) |
| MY (1) | MY140576A (fr) |
| NO (1) | NO20080284L (fr) |
| NZ (2) | NZ563049A (fr) |
| PL (1) | PL1901734T3 (fr) |
| PT (1) | PT1901734E (fr) |
| RS (1) | RS51569B (fr) |
| SI (1) | SI1901734T1 (fr) |
| TN (1) | TNSN07478A1 (fr) |
| TW (1) | TWI366460B (fr) |
| WO (1) | WO2006133941A2 (fr) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| TWI369203B (en) | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
| WO2006063109A2 (fr) * | 2004-12-09 | 2006-06-15 | Insys Therapeutics, Inc. | Formulations de dronabinol stable a temperature de laboratoire |
| KR100753959B1 (ko) * | 2006-01-12 | 2007-08-31 | 에이펫(주) | 기판 건조장치를 이용한 기판 건조방법 |
| CA2657332A1 (fr) * | 2006-07-14 | 2008-01-17 | Wine, Harvey | Formulations transdermiques de cannabinoides de synthese et de silice nanocolloidale |
| US20080069871A1 (en) * | 2006-07-21 | 2008-03-20 | Vaughn Jason M | Hydrophobic abuse deterrent delivery system |
| WO2008019146A2 (fr) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Formulations aqueuses de dronabinol |
| US8039509B2 (en) * | 2006-11-10 | 2011-10-18 | Johnson Matthey Public Limited Company | Composition comprising (−)-Δ9-trans-tetrahydrocannabinol |
| US8980940B2 (en) | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| PT2176208E (pt) * | 2007-07-30 | 2015-05-11 | Zynerba Pharmaceuticals Inc | Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos |
| WO2009020666A1 (fr) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Formulations liquides à usage oral de cannabinoïdes et procédés de traitement avec celles-ci |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| EP2534958A1 (fr) | 2007-12-14 | 2012-12-19 | AeroDesigns, Inc | Administration de produits alimentaires sous forme d'aérosols |
| GB0807915D0 (en) * | 2008-05-01 | 2008-06-04 | Resolution Chemicals Ltd | Production of delta 9 tetrahydrocannabinol |
| BRPI1014139A2 (pt) * | 2009-06-29 | 2016-04-26 | Bender Analytical Holding Bv | sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo. |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| CN102946870A (zh) | 2010-05-10 | 2013-02-27 | 欧洲凯尔特公司 | 包含氢吗啡酮和纳洛酮的药物组合物 |
| US9901540B2 (en) | 2010-05-10 | 2018-02-27 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
| EP2568968B1 (fr) | 2010-05-10 | 2017-07-12 | Euro-Celtique S.A. | Fabrication de granules libres de principes actifs et comprimés les contenant |
| US8629177B2 (en) * | 2010-08-24 | 2014-01-14 | Aphios Corporation | Nanoencapsulated delta-9-tetrahydrocannabinol |
| US8703727B2 (en) * | 2010-08-24 | 2014-04-22 | Aphios Corporation | Nanotechnology formulation of poorly soluble compounds |
| EP2701534A1 (fr) | 2011-04-28 | 2014-03-05 | ACME Specialty Products, LLC | Compositions de masquage du goût et leurs formes comestibles |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10350251B2 (en) * | 2012-03-28 | 2019-07-16 | Keith Gerald Freeman | Medical compositions, methods of making and using those compositions, and kits including those compositions |
| WO2013179264A2 (fr) * | 2012-05-30 | 2013-12-05 | Universidad Andres Bello | Utilisation de composés qui modulent sélectivement la libération astrocytaire de substances par les hémicanaux de connexine et de pannexine, sans influencer les jonctions communicantes, pour le traitement des troubles psychiatriques |
| US9345771B2 (en) | 2012-10-04 | 2016-05-24 | Insys Development Company, Inc. | Oral cannabinoid formulations |
| US10265293B2 (en) | 2012-10-04 | 2019-04-23 | Insys Development Company, Inc. | Oral cannabinoid formulations |
| US11253472B2 (en) | 2012-10-04 | 2022-02-22 | Benuvia Therapeutics Llc | Oral cannabinoid formulations |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| BR112015019180A8 (pt) | 2013-02-12 | 2018-01-30 | Corbus Pharmaceuticals Inc | ácidos tetrahidrocanabinol-11-óicos ultrapuros |
| EP3607941A1 (fr) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Formulations de poudre sèche et procédés d'utilisation |
| US9943491B2 (en) | 2013-10-29 | 2018-04-17 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
| WO2015065180A1 (fr) | 2013-10-29 | 2015-05-07 | Echo Pharmaceuticals B.V. | Comprimé contenant du delta 9-tétrahydrocannabinol, procédé de fabrication associé et utilisation de ce comprimé pour un traitement oral |
| WO2015071380A1 (fr) | 2013-11-13 | 2015-05-21 | Euro-Celtique S.A. | Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes |
| WO2015106108A2 (fr) * | 2014-01-13 | 2015-07-16 | Kannalife, Inc. | Nouveaux 1,3-benzène diols fonctionnalisés et leur procédé d'utilisation pour le traitement de l'encéphalopathie hépatique |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| US10610512B2 (en) | 2014-06-26 | 2020-04-07 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| EP3161140A4 (fr) * | 2014-06-27 | 2017-12-20 | National Research Council of Canada | Acide cannabichroménique synthase tirée de cannabis sativa |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US20160143972A1 (en) * | 2014-11-21 | 2016-05-26 | Cannamark Inc. | Method and apparatus for preparing a solid form of cannabinoid |
| AU2015385825A1 (en) | 2015-03-10 | 2017-10-05 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA2999032A1 (fr) * | 2015-09-24 | 2017-03-30 | Pasenture, Inc. | Compositions a base de cannabinoides et leurs procedes de production |
| ES2731367T3 (es) * | 2016-02-11 | 2019-11-15 | Gelpell Ag | Formulaciones de cannabinoides sólidas orales, métodos para producir y utilizar las mismas |
| US10542770B2 (en) | 2016-03-18 | 2020-01-28 | Aceso Wellness LLC | Cannabinoid emulsion product and process for making the same |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| MX2018012913A (es) | 2016-04-22 | 2019-01-30 | Receptor Life Sciences Inc | Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion. |
| EP3472307A4 (fr) * | 2016-06-15 | 2020-03-25 | Ojai Energetics PBC | Procédés et compositions de potentialisation de thérapies de cellules souches |
| CA3026794A1 (fr) | 2016-06-28 | 2018-01-04 | Trichomeshell Ltd. | Forme pharmaceutique destinee a etre vaporisee et fumee |
| US9717683B1 (en) | 2016-06-29 | 2017-08-01 | Ep Pharma, Llc | Low-temperature inhalation administration of cannabinoid entities |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| EA201892396A1 (ru) * | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| US20190224117A1 (en) * | 2017-06-14 | 2019-07-25 | Yury Leon Shmerlis | Cannabis Extract Chewing Gum |
| US11168047B2 (en) | 2017-08-07 | 2021-11-09 | Enantia, S.L. | Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol |
| CA3072768C (fr) * | 2017-08-27 | 2024-06-11 | Rhodes Technologies | Compositions pharmaceutiques destinees au traitement d'affections ophtalmiques |
| AU2017432640B2 (en) | 2017-09-22 | 2023-11-30 | Vectura Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| US10220061B1 (en) | 2017-09-26 | 2019-03-05 | Cynthia Denapoli | Method of reducing stress and anxiety in equines |
| US11179340B2 (en) * | 2017-12-29 | 2021-11-23 | TGC Network LLC | Cannabidiol dosage form |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| CA3089994A1 (fr) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Poudre de chanvre |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| US20200046787A1 (en) * | 2018-07-18 | 2020-02-13 | Glatt Gmbh | Extended release formulations of cannabinoids |
| EP3833369A4 (fr) | 2018-08-08 | 2022-05-04 | Neptune Wellness Solutions Inc. | Procédé d'extraction à froid de cannabinoïdes et de terpènes présents dans le cannabis par des solvants organiques |
| JP2022502471A (ja) * | 2018-10-10 | 2022-01-11 | ティルレイ，インコーポレイティド | 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 |
| EP3864000A4 (fr) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | Synthèse du cannabigérol |
| WO2020089424A1 (fr) | 2018-10-31 | 2020-05-07 | Enantia, S.L. | Compositions solides de co-cristaux de cannabinoïdes |
| MX2021006912A (es) | 2018-12-11 | 2021-08-24 | Disruption Labs Inc | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. |
| US20220071256A1 (en) * | 2018-12-14 | 2022-03-10 | Natural Extraction Systems, LLC | Compositions and methods related to anionic cannabinoid molecules |
| US10609944B1 (en) | 2018-12-14 | 2020-04-07 | Natural Extraction Systems, LLC | Compositions comprising 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol |
| US10959961B2 (en) | 2018-12-14 | 2021-03-30 | Natural Extraction Systems, LLC | Methods of administering anionic cannabinoid molecules dissolved in water |
| WO2020176526A1 (fr) * | 2019-02-25 | 2020-09-03 | Paul Mendell | Procédés d'administration de suppléments nutritionnels et thérapeutiques à l'aide de produits alimentaires et médicamenteux |
| CN112062697B (zh) * | 2019-05-22 | 2023-09-01 | 上海特化医药科技有限公司 | 间苯多酚衍生物及其制备方法 |
| SG11202112677WA (en) * | 2019-05-23 | 2021-12-30 | Kare Chemical Tech Inc | Catalytic cannabinoid processes and precursors |
| WO2020264199A1 (fr) * | 2019-06-26 | 2020-12-30 | Natural Extraction Systems, LLC | Récipients, compositions, et procédés associés à des anions cannabinoïdes |
| KR20220064376A (ko) * | 2019-09-18 | 2022-05-18 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 흡입에 의한 전달을 위한 칸나비노이드의 조성물 |
| US11542243B1 (en) | 2019-09-26 | 2023-01-03 | FusionFarms, LLC | Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization |
| WO2021071967A1 (fr) * | 2019-10-09 | 2021-04-15 | Island Breeze Systems Ca, Llc | Compositions permettant l'administration par voie pulmonaire de cannabinoïdes, méthodes et systèmes associés |
| US20230339880A1 (en) * | 2019-10-11 | 2023-10-26 | Corbus Pharmaceuticals, Inc. | Compositions of ajulemic acid and uses thereof |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CA3155181A1 (fr) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Administration transdermique de cannabidiol |
| WO2021081140A1 (fr) * | 2019-10-21 | 2021-04-29 | Esolate Ltd | Composés superfins et production associée |
| GB2588457B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
| GB2588456B (en) * | 2019-10-25 | 2023-02-01 | Gw Res Ltd | Cannabinoid compound |
| WO2021096886A1 (fr) * | 2019-11-11 | 2021-05-20 | Natural Extraction Systems, LLC | Procédés de séparation de cannabinoïdes à partir d'impuretés par cristallisation |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| WO2021195540A1 (fr) * | 2020-03-26 | 2021-09-30 | Radient Technologies Innovations Inc. | Composition à base de cannabinoïdes pour l'atténuation d'effets viraux |
| EP4153306A4 (fr) | 2020-05-22 | 2024-06-26 | Ilera Derm LLC | Compositions pour traiter l'acné et des maladies dermatologiques |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| IL278286B (en) | 2020-10-25 | 2021-06-30 | Fine Can Ltd | Cannabis powders and their uses |
| US20240308943A1 (en) * | 2020-11-29 | 2024-09-19 | Aphios Corporation | Extraction, separation and purification of cannabinoids from cannabis staiva and other marijuana biomass |
| US20220317097A1 (en) * | 2021-04-05 | 2022-10-06 | Grant Kraus | Atmospheric Triphasic Chromatography (ATC) method |
| WO2022232574A1 (fr) | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procédés de fabrication et leurs utilisations |
| US20220387256A1 (en) * | 2021-06-03 | 2022-12-08 | Kent Byron | Vial With Metered Dispenser |
| WO2023015102A1 (fr) * | 2021-07-26 | 2023-02-09 | Rapid Therapeutic Sciences Laboratories, Inc. | Procédé de production d'isolat de cbd |
| EP4124336B1 (fr) | 2021-07-30 | 2023-10-25 | Cannamedical Pharma GmbH | Timbre transmucosal comprenant un cannabinoïde et/ou un opioïde |
| CN115784836A (zh) * | 2022-12-08 | 2023-03-14 | 南京康立瑞生物科技有限公司 | 一种高选择性的制备反式-薄荷基-2,8-二烯-1-醇的方法 |
| WO2024160792A1 (fr) | 2023-01-30 | 2024-08-08 | Cannamedical Pharma Gmbh | Timbre transmucosal amélioré comprenant un cannabinoïde et/ou un opioïde |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2744938A (en) * | 1952-07-24 | 1956-05-08 | Universal Oil Prod Co | Removal of color impurities from organic compounds |
| US3507885A (en) | 1966-03-25 | 1970-04-21 | Hoffmann La Roche | 3-alkyl-6h-dibenzo(b,d)pyrans |
| CH481911A (de) | 1967-05-19 | 1969-11-30 | Theodor Dr Petrzilka | Verfahren zur Herstellung von tricyclischen Verbindungen |
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3668224A (en) * | 1970-07-02 | 1972-06-06 | Theodor Petrzilka | PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4025516A (en) | 1975-06-23 | 1977-05-24 | The John C. Sheehan Institute For Research, Inc. | Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans |
| US4381399A (en) | 1981-12-21 | 1983-04-26 | Aerojet-General Corporation | Purification of tetrahydrodibenzo[b,d]pyrans from crude synthetic mixtures |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| DE4100441A1 (de) | 1991-01-09 | 1992-07-16 | Mack Chem Pharm | Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol |
| US6703418B2 (en) | 1991-02-26 | 2004-03-09 | Unimed Pharmaceuticals, Inc. | Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection |
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| US5389375A (en) * | 1993-05-21 | 1995-02-14 | University Of Mississippi | Stable suppository formulations effecting bioavailability of Δ9 -thc |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| ES2247604T3 (es) | 1995-06-12 | 2006-03-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa. |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US6328992B1 (en) | 1997-03-03 | 2001-12-11 | Lawrence L. Brooke | Cannabinoid patch and method for cannabis transdermal delivery |
| US6132762A (en) | 1997-05-05 | 2000-10-17 | Cristobal; Walter | Transcutaneous application of marijuana |
| US5932557A (en) | 1997-08-12 | 1999-08-03 | Mustafa; S. Jamal | Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments |
| US6162829A (en) | 1997-10-17 | 2000-12-19 | Atlantic Pharmaceuticals, Inc. | (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics |
| GB9726916D0 (en) | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| DE69910373T2 (de) | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | Analgetische und immunomodulierende cannabinoiden |
| US6365416B1 (en) | 1998-10-26 | 2002-04-02 | The University Of Mississippi | Method of preparing delta-9-tetrahydrocannabinol |
| US6509005B1 (en) | 1998-10-27 | 2003-01-21 | Virginia Commonwealth University | Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler |
| TW507028B (en) * | 1999-02-12 | 2002-10-21 | Asahi Chemical Ind | A moisture-absorbable synthetic fiber with an improved moisture-release property |
| FI990915A0 (fi) | 1999-04-23 | 1999-04-23 | Orion Yhtymae Oyj | Jauheinhalaattori |
| US6403126B1 (en) * | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
| US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
| US6747058B1 (en) | 1999-08-20 | 2004-06-08 | Unimed Pharmaceuticals, Inc. | Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor |
| US6943266B1 (en) | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
| WO2001028329A1 (fr) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Ligands selectifs de recepteurs (cb2) de cannabinoides peripheriques |
| US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
| IL132661A (en) | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| US6794544B2 (en) * | 2000-03-10 | 2004-09-21 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| US6620351B2 (en) | 2000-05-24 | 2003-09-16 | Auburn University | Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer |
| GB2368061B (en) | 2000-10-20 | 2005-05-11 | Gw Pharmaceuticals Ltd | Dose dispensing apparatus |
| KR100960200B1 (ko) | 2000-10-30 | 2010-05-27 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
| CH695661A5 (de) | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| EP1409473A2 (fr) * | 2001-03-07 | 2004-04-21 | Websar Innovations Inc. | Conversion de cbd en $g(d)?8 -thc et en $g(d)?9 -thc |
| US20030050334A1 (en) * | 2001-04-30 | 2003-03-13 | Murty Ram B. | Process for extraction of Delta-9-Tetrahydrocannabinol and other related cannabinoids and preparation of specific strength marijuana cigarettes |
| GB0112752D0 (en) * | 2001-05-25 | 2001-07-18 | Johnson Matthey Plc | Synthesis of cannabinoids |
| PT1474412E (pt) | 2002-02-01 | 2008-07-04 | Resolution Chemicals Ltd | Produção do delta9-tetra-hidrocanabinol |
| AU2002242779A1 (en) | 2002-02-21 | 2003-09-09 | Timothee Biel | Device for driving motor vehicles, in particular with hybrid propulsion |
| ES2342660T3 (es) * | 2002-02-26 | 2010-07-12 | Astrazeneca Ab | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. |
| UA79281C2 (en) * | 2002-04-03 | 2007-06-11 | Solvay Pharm Bv | Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof |
| US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| DK1530469T3 (da) | 2002-08-20 | 2009-05-04 | Euro Celtique Sa | Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist |
| US20040229939A1 (en) | 2003-02-14 | 2004-11-18 | Chowdhury Dipak K. | Tetrahydrocannabinol compositions and methods of manufacture and use thereof |
| TW589663B (en) | 2003-05-12 | 2004-06-01 | Au Optronics Corp | Flat panel display and manufacturing method thereof |
| EP1696929A4 (fr) * | 2003-11-05 | 2010-02-24 | Unimed Pharmaceuticals Inc | Compositions de delta-9-thc et methodes de traitement de symptomes lies la sclerose en plaques |
| GB0329635D0 (en) * | 2003-12-23 | 2004-01-28 | Johnson Matthey Plc | Process for purifying trans-tetrahydrocannabinol |
| CN1997636B (zh) * | 2004-07-19 | 2011-09-28 | 希莱格有限公司 | 获得纯四氢大麻酚的方法 |
| SE0402485D0 (sv) * | 2004-10-13 | 2004-10-13 | Astrazeneca Ab | Polymorph of N,N-Diethyl-4-(3-Fluorophenyl-Piperidin-4-Ylidene-Methyl)-Benzamide Hydrochloride salt |
| GB0425445D0 (en) * | 2004-11-18 | 2004-12-22 | Smithkline Beecham Corp | Novel compositions |
| TWI369203B (en) * | 2004-11-22 | 2012-08-01 | Euro Celtique Sa | Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol |
-
2006
- 2006-05-29 TW TW095119006A patent/TWI366460B/zh not_active IP Right Cessation
- 2006-06-08 MY MYPI20062662A patent/MY140576A/en unknown
- 2006-06-14 EA EA200800056A patent/EA016813B1/ru not_active IP Right Cessation
- 2006-06-14 EP EP06754384A patent/EP1901734B1/fr active Active
- 2006-06-14 EP EP10011149A patent/EP2279735A3/fr not_active Withdrawn
- 2006-06-14 KR KR1020107019283A patent/KR20100102237A/ko active Search and Examination
- 2006-06-14 RS RS20110047A patent/RS51569B/en unknown
- 2006-06-14 JP JP2008516233A patent/JP2008543800A/ja not_active Withdrawn
- 2006-06-14 BR BRPI0612922-6A patent/BRPI0612922A2/pt not_active IP Right Cessation
- 2006-06-14 CA CA002612061A patent/CA2612061A1/fr not_active Abandoned
- 2006-06-14 EP EP10011148A patent/EP2263667A3/fr not_active Withdrawn
- 2006-06-14 AU AU2006257059A patent/AU2006257059C1/en not_active Ceased
- 2006-06-14 SI SI200630894T patent/SI1901734T1/sl unknown
- 2006-06-14 DK DK06754384.3T patent/DK1901734T3/da active
- 2006-06-14 PL PL06754384T patent/PL1901734T3/pl unknown
- 2006-06-14 AT AT06754384T patent/ATE489085T1/de active
- 2006-06-14 PT PT06754384T patent/PT1901734E/pt unknown
- 2006-06-14 MX MX2007016051A patent/MX2007016051A/es active IP Right Grant
- 2006-06-14 WO PCT/EP2006/005761 patent/WO2006133941A2/fr active Application Filing
- 2006-06-14 NZ NZ563049A patent/NZ563049A/en not_active IP Right Cessation
- 2006-06-14 KR KR1020137014701A patent/KR20130067323A/ko not_active Application Discontinuation
- 2006-06-14 AP AP2007004247A patent/AP2405A/xx active
- 2006-06-14 KR KR1020087001151A patent/KR20080026176A/ko active Search and Examination
- 2006-06-14 DE DE602006018466T patent/DE602006018466D1/de active Active
- 2006-06-16 US US11/455,256 patent/US20070072939A1/en not_active Abandoned
- 2006-06-16 AR ARP060102564A patent/AR054064A1/es not_active Application Discontinuation
- 2006-07-14 NZ NZ598030A patent/NZ598030A/xx not_active IP Right Cessation
-
2007
- 2007-12-13 IL IL188150A patent/IL188150A0/en unknown
- 2007-12-14 TN TNP2007000478A patent/TNSN07478A1/fr unknown
- 2007-12-17 EC EC2007008023A patent/ECSP078023A/es unknown
-
2008
- 2008-01-14 MA MA30572A patent/MA29630B1/fr unknown
- 2008-01-15 NO NO20080284A patent/NO20080284L/no not_active Application Discontinuation
- 2008-01-15 CR CR9662A patent/CR9662A/es unknown
- 2008-08-27 HK HK08109560.3A patent/HK1118447A1/xx not_active IP Right Cessation
-
2011
- 2011-02-16 CY CY20111100199T patent/CY1111446T1/el unknown
- 2011-02-23 HR HR20110129T patent/HRP20110129T1/hr unknown
-
2012
- 2012-06-28 JP JP2012145087A patent/JP2012211172A/ja active Pending
-
2013
- 2013-06-05 CR CR20130263A patent/CR20130263A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110129T1 (hr) | Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol | |
| US9937168B2 (en) | Nicotine-containing pharmaceutical compositions | |
| CN112770726B (zh) | 大麻素的缓释配方 | |
| JP5981416B2 (ja) | ニコチン含有医薬組成物 | |
| EP2768479B1 (fr) | Excipients pour des compositions thérapeutiques contenant de la nicotine | |
| WO2021003467A1 (fr) | Compositions de dosage et procédés d'utilisation de composés psychédéliques | |
| JP2008543800A5 (fr) | ||
| US10111831B2 (en) | Chewable vehicle for mouth absorption | |
| RU2014150422A (ru) | Новая дозировка и препаративная форма | |
| RU2001123923A (ru) | Композиции, включающие формотерол и соль тиотропия | |
| RU2014140674A (ru) | Новая дозировка и препаративная форма | |
| Saigal et al. | Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension | |
| RU2008124825A (ru) | Органические соединения, включающие соль гликопиррония | |
| Pilcer et al. | Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis | |
| JP2021528495A (ja) | ケタミンを含む新規製剤 | |
| JP2020059744A (ja) | 肥満を処置するための化合物およびその使用方法 | |
| UA119774C2 (uk) | Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл) | |
| CN103476412B (zh) | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 | |
| TW200940062A (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| RU2015143927A (ru) | Деаморфизация высушенных распылением составов посредством смешивания распылением | |
| US20070218131A1 (en) | Effervescent formulations comprising desmopressin | |
| US20190029999A1 (en) | Compositions comprising melatonin | |
| RU2590978C1 (ru) | Капсулированный препарат для лечения простуды и способ его получения | |
| CA2456721C (fr) | Composition pharmaceutique comprenant salmeterol et budesonide pour le traitement de troubles respiratoires | |
| KR20110106005A (ko) | 근골격근계 통증치료제의 서방형제제 |